Recent studies have validated ClpP as both a genetic vulnerability and a pharmacological target in leukemia, with evidence supporting its dual therapeutic modulation, either by hyperactivation or inhibition, as both approaches ultimately collapse mitochondrial integrity and induce leukemic cell death. The gene discussed is CLPP; the disease is leukemia.